CDTRP 2026 Research Innovation Grant Competition Results

CDTRP is thrilled to announce the results of the CDTRP 2026 Research Innovation Grant Competition, made possible through our partnership with various esteemed organizations. We are proud to showcase all of the exciting projects that have been funded in this year’s competition.

We would like to extend our warmest congratulations to Dr. Paraish Misra and his team for being awarded the CDTRP KFOC Research Innovation Grant. We wish them all the best as they embark on their innovative project!

“The Kidney Foundation of Canada is excited to support this work which could see immunosuppression after transplantation as a thing of the past. While transplantation can provide a new outlook on life for many kidney patients, it is often accompanied by a lifelong complications resultant from the requirement to take medications to suppress the host immune system. Innovation that could contribute to the reduction of immunosuppressive medications, have the potential to result in meaningful change for the post transplant community, and increase the potential for transplant as a treatment in a larger percentage of the population.”

CDTRP KFOC Research Innovation Grant : Dr. Paraish Misra

Project Title: Personalized immunomodulation after kidney transplant using donor-derived thymic epithelial cells

Main affiliation: McGill University

Theme: 4 – Tailor an Optimal Immune System for Each Patient

Lay Abstract

Kidney transplants give people their lives back, but powerful drugs called immunosuppressants are needed to prevent the immune system from rejecting the organ. These medications are a double-edged sword – they increase the risk of infections, cancer, and other complications and still do not work perfectly for everyone. Because of these risks, some people are considered too frail for a transplant, and for those who do get transplanted, these drugs cannot be stopped without risking rejection.

This project explores a new way to protect kidney transplants without using immunosuppressants. I will collect cells that are naturally shed into the urine of transplant recipients. These cells come from the donor kidney and carry the donor’s genetic identity. After collecting these cells, I will convert them into induced pluripotent stem cells (iPSCs), a flexible cell type that can be grown into any tissue in the body. I will then guide these iPSCs to become thymic cells. The thymus is an organ that “trains” immune cells to recognize which tissues are part of the body and which are foreign.

My long‑term goal is to use this lab-grown donor thymus to “re‑educate” the immune system so it accepts the transplanted kidney as its own. If this works, it could one day reduce the amount of immunosuppressants people need, and possibly allow some patients to stop them altogether. This would make treatment easier, improve quality of life, and may allow more people, especially those who are older or medically fragile, to safely receive kidney transplants.